The present study was designed to investigate the potential of a novel class of vesicular system ‘proniosome’ as a carrier for transdermal delivery of loratadine proniosomal formulations. It was prepared by co-acervation phase separation method. The influence of factors like lipid concentration, cholesterol amount and drug content were studied. Span 60 was the most appropriate surfactant and yielded vesicle size and percentage encapsulation efficiency respectively. The developed formulation was characterized for drug release, zeta potential, particle size, release kinetics and ex-vivo permeation studies. The in-vitro loratadine proniosomes exhibited sustained release for 7 hrs. Zeta potential was found to be -52.3mV which indicates the stability of the formulation. The proniosomes F3 formulation shows entrapment efficiency of 90%. The skin permeation showed same pattern as that of in-vitro release profile across the cellophane membrane for 7 hr. stability studies indicated no significant changes in formulation at accelerated condition after a month.
Loading....